The resurgence risk of COVID-19 in the presence of immunity waning and ADE effect: a mathematical modelling study

  1. Weike Zhou
  2. Biao Tang
  3. Yao Bai
  4. Yiming Shao
  5. Yanni Xiao
  6. Sanyi Tang

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

Since the end of 2020, the mass vaccination has been actively promoted and seemed to be effective to bring the COVID-19 pandemic under control. However, the fact of immunity waning and the possible existence of antibody-dependent enhancement (ADE) make the situation uncertain. We developed a dynamic model of COVID-19 incorporating vaccination and immunity waning, which was calibrated by using the data of accumulative vaccine doses administered and the COVID-19 epidemic in 2020 in mainland China. We explored how long the current vaccination program can prevent China in a low risk of resurgence, and how ADE affects the long-term trajectory of COVID-19 epidemics. The prediction suggests that the vaccination coverage with at least one dose reach 95.87%, and with two-doses reach 77.92% on August 31, 2021. However, even with the mass vaccination, randomly introducing infected cases in the post-vaccination period can result in large outbreaks quickly in the presence of immunity waning, particularly for SARS-CoV-2 variants with higher transmission ability. The results showed that with the current vaccination program and a proportion of 50% population wearing masks, mainland China can be protected in a low risk of resurgence till 2023/01/18. However, ADE effect and higher transmission ability for variants would significantly shorten the protective period for more than 1 year. Furthermore, intermittent outbreaks can occur while the peak values of the subsequential outbreaks are decreasing, meaning that subsequential outbreaks boosted the immunity in the population level, which further indicating that catching-up vaccination program can help to mitigate the possible outbreaks, even avoid the outbreaks. The findings reveal that integrated effects of multiple factors, including immunity waning, ADE, relaxed interventions, and higher transmission ability of variants, make the control of COVID-19 much more difficult. We should get ready for a long struggle with COVID-19, and should not totally rely on COVID-19 vaccine.

Article activity feed

  1. ScreenIT

    SciScore for 10.1101/2021.08.25.21262601: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    NIH rigor criteria are not applicable to paper type.

    Table 2: Resources

    No key resources detected.

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  2. Version published to 10.1101/2021.08.25.21262601v1 on medRxiv